恩替卡韦联合多烯磷脂酰胆碱对慢性乙型肝炎合并非酒精性脂肪肝患者平均血小板体积血尿酸及TGFβ1的影响

doi:10.3969/j.issn.1006-6233.2021.07.008

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (1255 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect of entecavir combined with polyene phosphatidylcholine treatment on average platelet volume, blood uric acid and TGFβ1 in patients with chronic hepatitis B combined with non-alcoholic fatty liver disease. Methods: The 146 patients with CHB combined with NAFLD admitted to this hospital from January 2017 to August 2019 were retrospectively analyzed. According to different treatment methods, patients were divided into the conventional group (conventional + entecavir treatment), 68 cases, and the combined group (entecavir + polyene phosphatidylcholine treatment), 78 cases. The clinical effects, mean platelet volume (MPV), serum uric acid (BUA), transforming growth factor β1 (TGFβ1), liver function and adverse reactions after treatment were compared between the two groups. Results: After treatment, the total clinical effective rate of the conventional group was 75.00%, which was significantly lower than that of the combination group (88.46%) (P<0.05). After treatment, the levels of MPV, BUA, and TGFβ1 all declined, and the declining in the combined group after treatment was significantly greater than that in the conventional group(P<0.05). After treatment, the liver function of the two groups improved. After treatment, the differences in AST, TBIL, and ALB levels in the combined group before and after treatment were significantly greater than those in the conventional group(P<0.05). After treatment, the total incidence of adverse reactions was 1.47% in the conventional group and 2.56% in the combination group. There was no difference between the two groups (P>0.05). Conclusion: Entecavir combined with polyene phosphatidylcholine therapy can reduce the levels of MPV, BUA and TGFβ1 in patients with CHB and NFALD, delay the progression of the disease, improve liver function, and improve the therapeutic effect.

Key words： Entecavir Polyene phosphatidylcholine Chronic hepatitis B with non-alcoholic fatty liver disease Mean platelet volume Blood uric acid TGFβ1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiao
	SHI Jie
	et al

Cite this article:

LI Xiao,SHI Jie,et al. Effect of Entecavir Combined with Polyene Phosphatidylcholine on Average Platelet Volume Blood Uric Acid and TGFβ1 in Patients with Chronic Hepatitis B Combined with NAFLD[J]. HeBei Med, 2021, 27(7): 1094-1098.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.07.008 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I7/1094

[1] 张海丛,郭立杰,王超,等.不同种类药物所致药物性肝损伤临床特点研究[J].临床误诊误治,2019,281(1):45~50.
[2] 隋佳,于梦,朱淑珍,等.外周血细胞因子在慢性乙型肝炎的治疗效果判断的价值研究[J].分子诊断与治疗杂志,2019,11(5):408~413.
[3] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会,范建高,等.非酒精性脂肪性肝病防治指南(2018年更新版)[J].实用肝脏病杂志,2018,21(2):30~39.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中国肝脏病杂志:电子版,2015,(3):1~18.
[5] 李岩,娄宪芝,张晓旭.替比夫定联合水飞蓟宾治疗乙型肝炎肝硬化的临床疗效[J].保健医学研究与实践,2018,15(4):60~62.
[6] 任天棋,杨倩倩,马鹤铭,等.TAF治疗慢性乙型肝炎的研究进展[J].肝脏,2019,24(11):106~109.
[7] 段红岩.微生态制剂联合抗病毒治疗对乙肝肝硬化患者免疫功能及肝纤维化指标的影响[J].河北医学,2019,25(11):1861~1865.
[8] 高凌燕,陈杰,王江.软肝汤联合多烯磷脂酰胆碱与恩替卡韦治疗乙型肝炎并发肝硬化的疗效及对肝纤维化指标的影响[J].山西医药杂志,2020,49(6):49~51.
[9] 韩本丽,任娜.益气活血解毒方联合恩替卡韦治疗乙型病毒性肝炎肝硬变临床研究[J].中医学报,2018,33(5):159~162.
[10] 季文媛,卫佳琪.自拟疏肝抑纤经验方联合恩替卡韦片对慢性乙型肝炎肝纤维患者化肝功能,血清肝纤维化标志物及血清TGF-β1,IL-10,MMP-2水平的影响[J].环球中医药,2019,(4).
[11] 郭怡.四逆散加减联合多烯磷脂酰胆碱治疗酒精性肝纤维化疗效及对肝纤维化指标,TIMP-1,TGF-β1的影响[J].现代中西医结合杂志,2018,27(24):2645~2648.
[12] 李丽萍,闻名,刘长明,等.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎患者疗效及其对肝功能、肝纤维化和炎性反应的影响[J].疑难病杂志,2019,18(3):247~250.